Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
This study identifies LRG1 as a novel HER3 ligand that promotes metastatic colorectal cancer growth and shows that blocking the LRG1/HER3 axis inhibits tumor growth in vitro and in vivo.
bioRxiv · Feb 18, 2023 · PreprintCancer Biology
W. Zhang, M. Wright, M. Rathore, M. Zarei, A. Vaziri-Gohar, J. Winter, J. Brody, R. Wang
This study shows liver endothelial cells promote PDAC growth via HER3-AKT signaling, suggesting HER3-targeted therapies for HER3-positive metastatic PDAC.
bioRxiv · Jun 24, 2022 · PreprintCancer Biology
M. Zarei, O. Hajihassani, J. J. Hue, H. J. Graor, M. Rathore, A. Vaziri-Gohar, J. M. Asara, J. M. Winter, L. D. Rothermel
This study shows that inhibiting wild-type IDH1 enhances chemotherapy response in melanoma by reducing redox homeostasis and increasing reactive oxygen species.
bioRxiv · May 13, 2022Cancer Biology
A. Vaziri-Gohar, J. J. Hue, H. J. Graor, A. Abbas, M. Zarei, O. Hajihassani, G. Titomihelakis, J. Feczko, M. Rathore, R. Wang, M. Zarei, M. Goudarzi, R. Zhang, B. Willard, L. Zhang, , J. M. Winter
This study shows that high glucose levels increase the effectiveness of chemotherapy in pancreatic cancer by reducing glutathione biosynthesis, which enhances oxidative stress in cancer cells.
bioRxiv · Apr 29, 2022Cancer Biology
M. Rathore, M. Wright, R. Bhattacharya, F. Fan, A. Vaziri-Gohar, J. Winter, Z. Wang, S. Markowitz, J. Willis, L. Ellis, R. Wang
The paper shows liver endothelial cells promote HER3-mediated survival in KRAS wild-type and mutant colorectal cancer cells through secreted factors, suggesting HER3 as a therapeutic target regardless of KRAS mutation status.
bioRxiv · Apr 27, 2021 · PreprintCancer Biology